kandy-therapeutics.png
KaNDy Therapeutics Announces Positive Phase 2b Data in Post-Menopausal Women with its Lead Non-Hormonal Product NT-814
January 13, 2020 07:00 ET | KaNDy Therapeutics
KaNDy Therapeutics Announces Positive Phase 2b Data in Post-Menopausal Women with its Lead Non-Hormonal Product NT-814 ~Phase 2b dose range finding study showed rapid and highly significant...
kandy-therapeutics.png
KaNDy Therapeutics Announces Positive Phase 2b Data in Post-Menopausal Women with its Lead Non-Hormonal Product NT-814
January 13, 2020 02:00 ET | KaNDy Therapeutics
KaNDy Therapeutics Announces Positive Phase 2b Data in Post-Menopausal Women with its Lead Non-Hormonal Product NT-814 ~Phase 2b dose range finding study showed rapid and highly significant...
kandy-therapeutics.png
KaNDy Therapeutics announces the appointment of Andrew Kay as Independent Chairman of the Board
January 07, 2019 07:00 ET | KaNDy Therapeutics
KaNDy Therapeutics announces the appointment of Andrew Kay as Independent Chairman of the Board Stevenage, UK, 7 January 2018 - KaNDy Therapeutics, a clinical-stage company developing a potential...
kandy-therapeutics.png
KaNDy Therapeutics announces the appointment of Andrew Kay as Independent Chairman of the Board
January 07, 2019 02:00 ET | KaNDy Therapeutics
KaNDy Therapeutics announces the appointment of Andrew Kay as Independent Chairman of the Board Stevenage, UK, 7 January 2018 - KaNDy Therapeutics, a clinical-stage company developing a potential...
kandy-therapeutics.png
KaNDy Therapeutics announces initiation of Phase 2b trial of NT-814 for the treatment of troublesome post-menopausal symptoms
December 11, 2018 07:00 ET | KaNDy Therapeutics
KaNDy Therapeutics announces initiation of Phase 2b trial of NT-814 for the treatment of troublesome post-menopausal symptoms Stevenage, UK, 11 December 2018 - KaNDy Therapeutics, a clinical-stage...
kandy-therapeutics.png
KaNDy Therapeutics announces initiation of Phase 2b trial of NT-814 for the treatment of troublesome post-menopausal symptoms
December 11, 2018 02:00 ET | KaNDy Therapeutics
KaNDy Therapeutics announces initiation of Phase 2b trial of NT-814 for the treatment of troublesome post-menopausal symptoms Stevenage, UK, 11 December 2018 - KaNDy Therapeutics, a clinical-stage...